Paradigm Asset Management Co. LLC Reduces Position in Sanofi (NASDAQ:SNY)

Paradigm Asset Management Co. LLC decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 4.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,619 shares of the company’s stock after selling 200 shares during the period. Paradigm Asset Management Co. LLC’s holdings in Sanofi were worth $223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of SNY. Charles Schwab Investment Management Inc. grew its holdings in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after purchasing an additional 33,105 shares during the period. Arkadios Wealth Advisors lifted its position in shares of Sanofi by 19.0% during the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after buying an additional 751 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after acquiring an additional 16,780 shares during the period. JPMorgan Chase & Co. increased its holdings in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Finally, GFS Advisors LLC raised its stake in Sanofi by 1,017.9% during the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after acquiring an additional 11,655 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SNY. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Sanofi has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Trading Up 0.6 %

Shares of SNY opened at $54.46 on Friday. The firm has a market cap of $138.21 billion, a P/E ratio of 21.87, a price-to-earnings-growth ratio of 1.00 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a 50 day simple moving average of $50.95 and a two-hundred day simple moving average of $52.52.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.